Exxua: Dosage Form, Projected Sales, NCE-1 Date | Gepirone

Exxua

Exxua is an extended-release oral antidepressant for adults with major depressive disorder. It selectively activates serotonin 5‑HT1A receptors, offering symptom relief with low risk of sexual side effects.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

Molecule Name :

Gepirone
Innovator :

FABRE KRAMER PHARMACEUTICALS INC
Approval Date :

22-Sep-23
NCE-1 Date :

22-Sep-27
NCE Date :

22-Sep-28
Dosage Form :

Extended Release Tablets
Strength :

18.2mg, 36.3mg, 54.5mg and 72.6mg
Therapeutic Category :

Antidepressant
Revenue ($M) :

NA

Year-wise Projected Sales ($M) :

2025 :

17
2026 :

46
2027 :

88
2028 :

135
2029 :

165
2030 :

NA
2031 :

NA

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Exxua

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?